Masood Ahmed is the Vice President and Regional Compliance Officer, Asia & JPAC of Sanofi Group.

Masood started his career as finance professional with Beecham. He had held positions of CFO in Upjohn, Pharmacia, GSK & vice President Operations Pfizer before embarking on his role as Regional Compliance Officer with Schering-Plough.

Masood had significantly contributed in several merger and integration activities of giant pharmaceutical organizations which provided him unique opportunities of managing people, strategies and processes integration and shaping the corporate culture.

Masood has been intimately involved in the evolution of Pharmaceuticals industry's compliance environment in challenging markets in Asia.

Karen Eryou is currently Senior Director, Corporate Compliance, APAC for UCB. She has over 15 years of international work experience in the pharmaceutical industry including Clinical Operations, Quality Assurance, Auditing and Inspections, as well as Medical Affairs. She has focused on business practices, ethics and compliance topics for the past 5 years. Since 2011 Karen has been based in Shanghai where she was assigned to build the compliance function for UCB. Following the development and implementation of a comprehensive compliance program with the China team she now leads the compliance program for the Asia-Pacific region for UCB.

Maria Eugenia (Maru) Quindimil is Senior Director APAC at GEC Risk Advisory LLC, the global governance, risk, integrity, reputation and crisis advisory firm (www.GECRisk.com) serving executives, boards, investors and advisors in diverse sectors, growth stages and industries, primarily in the Americas, Europe and Africa. Client assignments range from strategic to tactical, including enterprise and specific risk assessments, crisis planning, integrity program development, codes of conduct, and customized education from the boardroom to the shop floor.

Ms. Quindimil, the former Executive Director, Regional Compliance Officer, Asia for Merck Sharp & Dohme, Asia Ltd., led regional Compliance groups, comprising 26 professional staff in 20 Asia Pacific countries (10,000 employees) for 8 years. She successfully implemented the Foreign Corrupt Practices Acts (FCPA) in the region, the first Merck region to significantly reduce corrupt practice risk; used Six Sigma methodologies to simplify processes and develop an innovative scorecard and electronic platform to review compliance programs at the country level and ensure follow up monitoring; and improved key risk areas, including 90% reduction in samples management cases the first year. She co-created Asia Pacific Escalation, Investigation, Remediation and Recognition guidelines that were adopted by Merck globally. During the last two years, she created a strong process to handle Third Parties contracted in different capacities enhancing their compliance programs and governance processes.

In 2015 she was internationally recognized by the World Women Congress Leadership organization for her outstanding contributions in the region with the "Women Leadership Achievement Award." This award is given to outstanding women professionals who have demonstrated vision, flair, acumen and management skills in an organization making changes and achieving results sponsored by World Federation of Marketing professionals, Stars of the Industry Group, Asia Confederation of Business and World CSR Day.

Throughout a career that has spanned 25 years, Maru has applied her background in pharmaceutical and pharmacological research into the commercial pharmaceutical sector where she led the development, launch and market growth of several new products across a diverse range of geographic sectors. She has received several awards and recognition for achieving targets and significantly exceeding sales budgets. Her commercial background provides a broader strategic view of the role of compliance in operations, and has influenced management, regional leadership and boards of directors through innovative systems and processes. Her focus is to bring behavioral changes among leaders as well as rank-and-file.

Known for a flexible and situational leadership style, she is committed to enabling and optimizing the performance of teams from diverse backgrounds and across different work environments.

Maru has led APEC Pharmaceutical sector meetings for the implementation of Pharmaceutical codes of conduct, is a current Board member of Asia Pacific Compliance Group, and has been Chair and Speaker at Asia Pacific Pharmaceutical Compliance Congress for the last 4 years as well as a frequent speaker for IFPMA. A native Argentinian, Maru has lived and worked in Latin America, Europe, the USA and Asia Pacific region, and is fluent in English, Spanish and Portugese.

Maru has degrees in Biochemistry and Pharmacy from Universidad de Buenos Aires, Argentina; MBA from Instituto de Altos Estudios Empresariales from Universidad Austral, Argentina, Human Resources Master degree from Centro Estudios Financieros, Spain and graduated from Strategic Leadership Program from Institute of Leadership, Otago University, New Zealand.

Accountable for driving Abbott's Regional Ethics and Compliance Program in Asia region across its hugely diversified businesses i.e. Nutritional Products, Diabetes Care, Medical Optics, Vascular, Diagnostics, Pharmaceuticals and Molecular. One goal in mind: Nurture a robust organisation wide mindset of Triple Lenses of Responsibilities Framework -- Ethics, Economics/Finance and the Law.

An accomplished International Ethics & Compliance professional with combined 18 years of proven track record from scaling up to sustaining the Compliance Program together with Global and Regional key stakeholders. Experienced leading complex Audits and Investigations that resulted in a more robust internal controls structure and FCPA/ Anti-Bribery Anti-Corruption detective and preventive measures being put in place.

An outstanding people manager whose leadership philosophy is having a clear vision, empowering, coaching and the right intervention.

A Harvard Business School trained and well regarded industry thought leader. Rhys is currently the co-chairperson for Asia Pharmaceutical Compliance Congress, faculty member of Seton Hall University's Asia-Pacific Healthcare Compliance Program, founding member of the Asia-Pacific Healthcare Compliance Industry Group and member of the Harvard Business School Healthcare Alumni Association.

Masood Ahmed is the Vice President and Regional Compliance Officer, Asia & JPAC of Sanofi Group.

Masood started his career as finance professional with Beecham. He had held positions of CFO in Upjohn, Pharmacia, GSK & vice President Operations Pfizer before embarking on his role as Regional Compliance Officer with Schering-Plough.

Masood had significantly contributed in several merger and integration activities of giant pharmaceutical organizations which provided him unique opportunities of managing people, strategies and processes integration and shaping the corporate culture.

Masood has been intimately involved in the evolution of Pharmaceuticals industry's compliance environment in challenging markets in Asia.

Cristopher Landrito is the Area Compliance Officer of Takeda Pharmaceuticals in Asia Pacific, based in Singapore. He is a qualified lawyer from the Philippines with experience in litigation, banking, tax, and in government regulatory matters, in addition to ethics and compliance. He has worked in various capacities in the banking, pharmaceutical and chemicals industries, as well as in the legislature. Before assuming his current role, Cris was the Regional Compliance Officer of the Merck KGaA Group in Asia Pacific, and, previously, its Legal Counsel for its ethical pharma division in Southeast Asia.

Redentor R. Romero is the APAC Director of Compliance for Teva Pharmaceutical Investments Singapore Pte Ltd, where he is responsible for formulating and developing the Compliance Program for Teva in Asia Pacific. He is a lawyer by profession and was the Regional Legal Counsel for AstraZeneca for the Asia Area before joining Teva. Prior to joining the pharma industry, he was in legal practice, focusing on litigation, contracts and labor law.

Belinda has more than 19 years of accounting experience incorporating 11 years in managing investigations, anti-corruption and litigation support engagements. She has led enquiries relating to corruption, bribery, conflict of interests, financial statement manipulations, assets misappropriation and computation of damages in Asia Pacific and Greater China where she lived for almost 6 years. Belinda's portfolio of clients included pharmaceutical, healthcare, medical devices, manufacturing and trading companies.

Reiner Gloor, a member of the Board of Trustees and Chairman of the Membership Committee of the Medicine Transparency Alliance (MeTA), works to improve access and affordability of medicines.

At MeTA, he represents the Pharmaceutical and Healthcare Association of the Philippines (PHAP), where he served as a PHAP Trustee for 27 years. He continues to be involved with PHAP on an advisory capacity.

Following his retirement from Zuellig Pharma in 2002, Reiner established and now heads a small virtual pharma company, buergli pharma inc. Buergli Pharma provides healthcare professionals (HCP) information on regenerative medicine research and carries a small range of quality affordable OTC and ethical products.

Maria Eugenia (Maru) Quindimil is Senior Director APAC at GEC Risk Advisory LLC, the global governance, risk, integrity, reputation and crisis advisory firm (www.GECRisk.com) serving executives, boards, investors and advisors in diverse sectors, growth stages and industries, primarily in the Americas, Europe and Africa. Client assignments range from strategic to tactical, including enterprise and specific risk assessments, crisis planning, integrity program development, codes of conduct, and customized education from the boardroom to the shop floor.

Ms. Quindimil, the former Executive Director, Regional Compliance Officer, Asia for Merck Sharp & Dohme, Asia Ltd., led regional Compliance groups, comprising 26 professional staff in 20 Asia Pacific countries (10,000 employees) for 8 years. She successfully implemented the Foreign Corrupt Practices Acts (FCPA) in the region, the first Merck region to significantly reduce corrupt practice risk; used Six Sigma methodologies to simplify processes and develop an innovative scorecard and electronic platform to review compliance programs at the country level and ensure follow up monitoring; and improved key risk areas, including 90% reduction in samples management cases the first year. She co-created Asia Pacific Escalation, Investigation, Remediation and Recognition guidelines that were adopted by Merck globally. During the last two years, she created a strong process to handle Third Parties contracted in different capacities enhancing their compliance programs and governance processes.

In 2015 she was internationally recognized by the World Women Congress Leadership organization for her outstanding contributions in the region with the "Women Leadership Achievement Award." This award is given to outstanding women professionals who have demonstrated vision, flair, acumen and management skills in an organization making changes and achieving results sponsored by World Federation of Marketing professionals, Stars of the Industry Group, Asia Confederation of Business and World CSR Day.

Throughout a career that has spanned 25 years, Maru has applied her background in pharmaceutical and pharmacological research into the commercial pharmaceutical sector where she led the development, launch and market growth of several new products across a diverse range of geographic sectors. She has received several awards and recognition for achieving targets and significantly exceeding sales budgets. Her commercial background provides a broader strategic view of the role of compliance in operations, and has influenced management, regional leadership and boards of directors through innovative systems and processes. Her focus is to bring behavioral changes among leaders as well as rank-and-file.

Known for a flexible and situational leadership style, she is committed to enabling and optimizing the performance of teams from diverse backgrounds and across different work environments.

Maru has led APEC Pharmaceutical sector meetings for the implementation of Pharmaceutical codes of conduct, is a current Board member of Asia Pacific Compliance Group, and has been Chair and Speaker at Asia Pacific Pharmaceutical Compliance Congress for the last 4 years as well as a frequent speaker for IFPMA. A native Argentinian, Maru has lived and worked in Latin America, Europe, the USA and Asia Pacific region, and is fluent in English, Spanish and Portugese.

Maru has degrees in Biochemistry and Pharmacy from Universidad de Buenos Aires, Argentina; MBA from Instituto de Altos Estudios Empresariales from Universidad Austral, Argentina, Human Resources Master degree from Centro Estudios Financieros, Spain and graduated from Strategic Leadership Program from Institute of Leadership, Otago University, New Zealand.

Fatima "Girlie" Garcia-Lorenzo is a Certified Child Life Specialist by the Child Life Council, USA. She completed her Child Life internship at the University of California San Francisco Hospital. She is a professional Child and Family Psychologist and holds experience in Human Resources, Organizational Diagnosis and Counseling.

Ms. Garcia-Lorenzo holds the distinction of being the First Filipino Ashoka Fellow. She was chosen because of her work as a social innovator in the field of children's health and public hospital system's change for the past 23 years.

Ms. Cynthia K. Magdaraog is currently president of the Philippine Society for Orphan Disorders, Inc., a non-stock, non-profit organization. She assumed the position in July 2006.

The society was established to assist persons (mostly children) afflicted with a rare disorder to access treatment and supportive care.

She is mother of a young man who has been living with a rare disease for the past 28 years now.

Prior to her involvement in PSOD, she was a businesswoman for the past 20 years assuming the function of President and CEO of their family businesses.

Ms. Magdaraog was a professional manager in the field of human resource development for various companies.

Jean-Luc Lowinski became Senior Vice President, Sanofi Asia on May 1st, 2012. In this role, Dr. Lowinski is responsible for Sanofi's business and growth in Greater China, Southeast Asia (Philippines, Thailand, Indonesia, Singapore/Malaysia), and Indochina (Vietnam, Laos, Cambodia).

Prior to joining Sanofi, Dr. Lowinski built a successful career in Pharmaceuticals, Consumer Healthcare and Animal Health. He began his career in the French Army as a technical volunteer before becoming a veterinary. He joined Bayer Germany in 1992 and held various positions including Head of Operations in Singapore, India, Thailand, China and Japan. In 2003, he became Head of Bayer Healthcare, China. He then became Head of Bayer Healthcare, Asia Pacific, at the end of 2004 before being appointed President, Bayer Yakuhin, Japan in 2007. In 2010, he became Global Head of the Animal Health Division at Bayer.

Dr. Lowinski holds a Ph.D. in Veterinary Science from the University of Nantes, France and is a graduate from INSEAD. He is a French national, and he speaks French, English, German, Japanese and Chinese.

Professional Highlights
Twenty years of experience in the pharmaceutical/biotechnology industry that include leadership roles in general management, lifecycle and franchise management, marketing, sales, business development and 15 years of management responsibilities. Proven track record of consistency meeting or exceeding goals and financial targets. Proven ability to achieve success through strong strategic business planning and implementation, managing and leading change, deliberate decision-making and leading and mobilizing large and cross-functional teams to address complex business and organization challenges. Has worked in many markets around the world including the United States.

Education
Masters in Business Management- Asian Institute of Management, Manila, Philippines Trans Philippines Scholarship Awardee. Consistent Dean's List (Top Ten); Participant MBA International Student Program, Mc GILL UNIVERSITY, Montreal, Canada, Winter 1994
Bachelor of Science in Industrial Management Engineering minor in Chemical Engineering- DELA SALLE UNIVERSITY, Manila, Philippines, 1985-1989
Dean's List. Gold Medal Awardee for Best Thesis.

Beaver R. Tamesis, MD, 20-year experience in MSD (Merck in the U.S. and Canada) across several key franchises and in the Asia Pacific region. He joined MSD in 1995 as Medical Director for the Philippines and successfully established MSDs medical and scientific leadership. In 2002, he became Business Unit Director (BUD) for the Bone and Joint franchises. In the next two years, he became AP Regional Marketing Director for the Diabetes franchise, spearheading the launch of Januvia in seven countries. Since 2007, he has been BUD for the Cardiovascular and Metabolic franchise in the Philippines, and was recently appointed Market Access lead for the country.

Maria Eugenia (Maru) Quindimil is Senior Director APAC at GEC Risk Advisory LLC, the global governance, risk, integrity, reputation and crisis advisory firm (www.GECRisk.com) serving executives, boards, investors and advisors in diverse sectors, growth stages and industries, primarily in the Americas, Europe and Africa. Client assignments range from strategic to tactical, including enterprise and specific risk assessments, crisis planning, integrity program development, codes of conduct, and customized education from the boardroom to the shop floor.

Ms. Quindimil, the former Executive Director, Regional Compliance Officer, Asia for Merck Sharp & Dohme, Asia Ltd., led regional Compliance groups, comprising 26 professional staff in 20 Asia Pacific countries (10,000 employees) for 8 years. She successfully implemented the Foreign Corrupt Practices Acts (FCPA) in the region, the first Merck region to significantly reduce corrupt practice risk; used Six Sigma methodologies to simplify processes and develop an innovative scorecard and electronic platform to review compliance programs at the country level and ensure follow up monitoring; and improved key risk areas, including 90% reduction in samples management cases the first year. She co-created Asia Pacific Escalation, Investigation, Remediation and Recognition guidelines that were adopted by Merck globally. During the last two years, she created a strong process to handle Third Parties contracted in different capacities enhancing their compliance programs and governance processes.

In 2015 she was internationally recognized by the World Women Congress Leadership organization for her outstanding contributions in the region with the "Women Leadership Achievement Award." This award is given to outstanding women professionals who have demonstrated vision, flair, acumen and management skills in an organization making changes and achieving results sponsored by World Federation of Marketing professionals, Stars of the Industry Group, Asia Confederation of Business and World CSR Day.

Throughout a career that has spanned 25 years, Maru has applied her background in pharmaceutical and pharmacological research into the commercial pharmaceutical sector where she led the development, launch and market growth of several new products across a diverse range of geographic sectors. She has received several awards and recognition for achieving targets and significantly exceeding sales budgets. Her commercial background provides a broader strategic view of the role of compliance in operations, and has influenced management, regional leadership and boards of directors through innovative systems and processes. Her focus is to bring behavioral changes among leaders as well as rank-and-file.

Known for a flexible and situational leadership style, she is committed to enabling and optimizing the performance of teams from diverse backgrounds and across different work environments.

Maru has led APEC Pharmaceutical sector meetings for the implementation of Pharmaceutical codes of conduct, is a current Board member of Asia Pacific Compliance Group, and has been Chair and Speaker at Asia Pacific Pharmaceutical Compliance Congress for the last 4 years as well as a frequent speaker for IFPMA. A native Argentinian, Maru has lived and worked in Latin America, Europe, the USA and Asia Pacific region, and is fluent in English, Spanish and Portugese.

Maru has degrees in Biochemistry and Pharmacy from Universidad de Buenos Aires, Argentina; MBA from Instituto de Altos Estudios Empresariales from Universidad Austral, Argentina, Human Resources Master degree from Centro Estudios Financieros, Spain and graduated from Strategic Leadership Program from Institute of Leadership, Otago University, New Zealand.

Katsumi KOJIMA is a Corporate officer, Country Compliance officer Japan of Sanofi Group, based in Tokyo, Japan. He is a member of the Code Compliance Committee, the Japanese Pharmaceutical Manufacturers Association (JPMA) and a member of the International Federation of Pharmaceutical Manufacturers and associations (IFPMA) Code Compliance Network.

He has been working for compliance field in the pharmaceutical and medical device industries over ten (10) years. He engaged in a speaker and a panellist on compliance topics in various conferences, such as "How Do I Know It's Working? Key Performance Indicators, Metrics and More" at Asia-Pacific Economic Cooperation (Nanjing, China) in 2014, "Venues & Locations of Third Party Conferences: What is Appropriate" at Advanced Medical Technology Association and Medical Technology Association of Australia Compliance Conference (Singapore) in 2014 and "Australia and Japan transparency updates" at the Global MedTech Compliance Conference (Barcelona, Spain) in 2014.

He earned LLB from Waseda University (Tokyo, Japan) and LLM from Hitotsubashi University (Tokyo, Japan). In addition, he received certification from INSEAD Compliance Implementation Leadership 1 (Fontainebleau, France) and Seton Hall Law School Aisa-Pacific Healthcare Compliance (Singapore). Since 2010, he has served as a Visiting Lecturer at Kyoto Prefectural University of Medicine (Kyoto, Japan).

Cristopher Landrito is the Area Compliance Officer of Takeda Pharmaceuticals in Asia Pacific, based in Singapore. He is a qualified lawyer from the Philippines with experience in litigation, banking, tax, and in government regulatory matters, in addition to ethics and compliance. He has worked in various capacities in the banking, pharmaceutical and chemicals industries, as well as in the legislature. Before assuming his current role, Cris was the Regional Compliance Officer of the Merck KGaA Group in Asia Pacific, and, previously, its Legal Counsel for its ethical pharma division in Southeast Asia.

Masood Ahmed is the Vice President and Regional Compliance Officer, Asia & JPAC of Sanofi Group.

Masood started his career as finance professional with Beecham. He had held positions of CFO in Upjohn, Pharmacia, GSK & vice President Operations Pfizer before embarking on his role as Regional Compliance Officer with Schering-Plough.

Masood had significantly contributed in several merger and integration activities of giant pharmaceutical organizations which provided him unique opportunities of managing people, strategies and processes integration and shaping the corporate culture.

Masood has been intimately involved in the evolution of Pharmaceuticals industry's compliance environment in challenging markets in Asia.

Fatima "Girlie" Garcia-Lorenzo is a Certified Child Life Specialist by the Child Life Council, USA. She completed her Child Life internship at the University of California San Francisco Hospital. She is a professional Child and Family Psychologist and holds experience in Human Resources, Organizational Diagnosis and Counseling.

Ms. Garcia-Lorenzo holds the distinction of being the First Filipino Ashoka Fellow. She was chosen because of her work as a social innovator in the field of children's health and public hospital system's change for the past 23 years.

Ms. Cynthia K. Magdaraog is currently president of the Philippine Society for Orphan Disorders, Inc., a non-stock, non-profit organization. She assumed the position in July 2006.

The society was established to assist persons (mostly children) afflicted with a rare disorder to access treatment and supportive care.

She is mother of a young man who has been living with a rare disease for the past 28 years now.

Prior to her involvement in PSOD, she was a businesswoman for the past 20 years assuming the function of President and CEO of their family businesses.

Ms. Magdaraog was a professional manager in the field of human resource development for various companies.

Riza holds degrees in AB English and Bachelor of Laws. She started her legal career in 2000 specializing in commercial law, IP, tax and labor. She moved to Sanofi Philippines in 2006, becoming Legal, Public Affairs and Communications Director there, before joining Novartis in 2011.

Riza was an active member of the PHAP Committees on Public Affairs (2007-2011) and Integrity & Compliance (2012-2015).

Chi is a Forensic Technology Partner with EY's Fraud Investigation & Dispute Services practice in Shanghai. Chi has more than 14 years of experience in financial and enterprise data analytics and has worked in the United States, Australia and Greater China. He has extensive experience utilizing analytical software packages to join disparate data sets into a single repository, performing various analyses upon them, and identifying trends, patterns and outliers to detect fraud. Chi has led the design of a number of complex analytical engines leveraging predictive analysis, statistical modeling, data visualization, and text mining to help clients build continuous monitoring systems to identify fraudulent or high risk transactions timely and efficiently. He is also experienced in providing clients leading forensic data analytics solutions, including AML analytics, anti-bribery and anti-corruption analytics, Fraud Triangle analytics, third-party due diligence, business intelligence, text mining, and statistical anomaly detection. Chi has a Bachelor's Degree in Information Science from Peking University and a Master's Degree in Computer Science from Suffolk University. He is a Certified Fraud Examiner (CFE) and a Certified Information Systems Auditor (CISA).

Eugene Chen is a partner based in Hogan Lovells' Shanghai office, and is one of the few US-trained and experienced litigators located full-time in China to advise clients regarding advantages and liabilities of international dispute resolution. His practice focuses on cross-border disputes and investigations in the United States, China, and elsewhere in Asia.

Eugene began his career as a food and drug regulatory lawyer in Washington, DC, and has extensive litigation, compliance, and regulatory experience with the life sciences industry. For the past eight years, he has assisted clients with anti-corruption investigations and policy development in China, as well as enforcement actions by Chinese and U.S. authorities.

Seck Yee Chung leads the Firm's M&A, IT/C and Pharmaceutical &Healthcare practices in Vietnam. He is highly regarded in his field -- Chambers Global, Chambers Asia, and Asia Pacific Legal 500.

Mr. Seck has dealt with a wide range of investment projects and major M&A deals, and advised and assisted on corporate, commercial and regulatory compliance matters. This includes foreign direct investment, market access and licensing, private and public M&A, securities transfer and disclosures, competition and anti-corruption compliance, commercial promotions and marketing, data use and privacy, over a diverse range of industries, from consumer products, pharmaceuticals, medical devices, clinical trials, cosmetics, and food & beverage, to manufacturing, property, IT services, and aviation.

Laurent Clerc is regulatory affairs expert at BMI SYSTEM. He holds a Master of Health Law, a Master of Quality Assurance and an executive MBA. Co-founder of BMI SYSTEM, he has a professional background of more than 18 years serving the pharmaceutical industry and hospitals within consulting firms specialised in regulatory affairs.

Mohit is an Executive Director in Risk Consulting and leads the Life Sciences & Health Care industry in Southeast Asia. With 20 years of experience in Consulting and Life Sciences industries, he possesses in-depth expertise in enabling business growth strategies, transformations in Sales & Marketing, Finance and IT functions. He has extensive experience in delivering shared services, digital, enterprise applications and outsourcing initiatives.

Divina Ilas-Panganiban is a partner in Quisumbing Torres' Intellectual Property and Information Technology & Communications practice group. Her practice focuses on the protection of intellectual property rights, licensing and IP commercialization transactions, including franchising arrangements; regulatory and compliance matters, and IP litigation cases. She currently serves as a member of the Board of Directors of the Philippine Chapter of Licensing Executives Society International and is an accredited arbitrator of the Philippine Intellectual Property Office and the Philippine Dispute Resolution Center. Ms. Panganiban often serves as resource speaker in local and international seminars on IP and IT laws, including data privacy protection and social media.

Most recently, ten years in global Life Sciences Compliance and Governance supporting International markets - areas of focus include US Foreign Corrupt Practices Act, UK Bribery Act, Codes of Business Conduct, due diligence reviews, and supporting investigations and corrective actions.

Maria Eugenia (Maru) Quindimil is Senior Director APAC at GEC Risk Advisory LLC, the global governance, risk, integrity, reputation and crisis advisory firm (www.GECRisk.com) serving executives, boards, investors and advisors in diverse sectors, growth stages and industries, primarily in the Americas, Europe and Africa. Client assignments range from strategic to tactical, including enterprise and specific risk assessments, crisis planning, integrity program development, codes of conduct, and customized education from the boardroom to the shop floor.

Ms. Quindimil, the former Executive Director, Regional Compliance Officer, Asia for Merck Sharp & Dohme, Asia Ltd., led regional Compliance groups, comprising 26 professional staff in 20 Asia Pacific countries (10,000 employees) for 8 years. She successfully implemented the Foreign Corrupt Practices Acts (FCPA) in the region, the first Merck region to significantly reduce corrupt practice risk; used Six Sigma methodologies to simplify processes and develop an innovative scorecard and electronic platform to review compliance programs at the country level and ensure follow up monitoring; and improved key risk areas, including 90% reduction in samples management cases the first year. She co-created Asia Pacific Escalation, Investigation, Remediation and Recognition guidelines that were adopted by Merck globally. During the last two years, she created a strong process to handle Third Parties contracted in different capacities enhancing their compliance programs and governance processes.

In 2015 she was internationally recognized by the World Women Congress Leadership organization for her outstanding contributions in the region with the "Women Leadership Achievement Award." This award is given to outstanding women professionals who have demonstrated vision, flair, acumen and management skills in an organization making changes and achieving results sponsored by World Federation of Marketing professionals, Stars of the Industry Group, Asia Confederation of Business and World CSR Day.

Throughout a career that has spanned 25 years, Maru has applied her background in pharmaceutical and pharmacological research into the commercial pharmaceutical sector where she led the development, launch and market growth of several new products across a diverse range of geographic sectors. She has received several awards and recognition for achieving targets and significantly exceeding sales budgets. Her commercial background provides a broader strategic view of the role of compliance in operations, and has influenced management, regional leadership and boards of directors through innovative systems and processes. Her focus is to bring behavioral changes among leaders as well as rank-and-file.

Known for a flexible and situational leadership style, she is committed to enabling and optimizing the performance of teams from diverse backgrounds and across different work environments.

Maru has led APEC Pharmaceutical sector meetings for the implementation of Pharmaceutical codes of conduct, is a current Board member of Asia Pacific Compliance Group, and has been Chair and Speaker at Asia Pacific Pharmaceutical Compliance Congress for the last 4 years as well as a frequent speaker for IFPMA. A native Argentinian, Maru has lived and worked in Latin America, Europe, the USA and Asia Pacific region, and is fluent in English, Spanish and Portugese.

Maru has degrees in Biochemistry and Pharmacy from Universidad de Buenos Aires, Argentina; MBA from Instituto de Altos Estudios Empresariales from Universidad Austral, Argentina, Human Resources Master degree from Centro Estudios Financieros, Spain and graduated from Strategic Leadership Program from Institute of Leadership, Otago University, New Zealand.

Diva has thirteen years of consulting and auditing experience related to compliance issues in the pharmaceutical industry.

Presently as VP Compliance at Cegedim, Diva is responsible for compliance activities addressing transparency regulatory requirements (e.g. EFPIA, French Transparency Law).

Prior to joining Cegedim, Diva worked for Polaris, a consulting firm based in New York. He was a leader in the compliance practice. Diva also worked as a corporate auditor and financial analyst with Sanofi in Paris and Frankfurt.

In 2012 he published the article, "Limiting Off-Label Exposure in Speaker Programs" in RxCompliance Report. Diva was awarded a master in management by the University of Sorbonne in Paris.

Andrew has over 5 years of professional experience working in Legal and Compliance. Andrew completed his studies at the University of Technology, Sydney earning a Bachelor of Law & Medical Science.

After graduating, Andrew took up a Compliance role at Novartis Pharmaceuticals Australia and New Zealand for 3 years before accepting a role at Sanofi ANZ in 2014 as the Country Compliance Officer. Andrew is responsible for managing the overall Compliance program including implementing effective SOPs and policies, conducting internal testing/monitoring and providing strategic compliance advice to the business units.

In 2015, Andrew received his Healthcare Compliance Certification from INSEAD, one of the top business schools in Europe. Andrew highly enjoys working on Compliance projects and finds it extremely rewarding partnering with the business units.

Yota Kikuchi is Manager of Compliance in Sanofi Japan, responsible in developing, implementing, training company policies, conducting due diligence, monitoring and investigations. He was the Vice Chair of the JPMA Code Practices Committee for 8 years until June 2015, involved in the establishment of the 2013 JPMA Code of Practice. He was also a member of the JPMA Transparency Taskforce to implement the JPMA Transparency Guidelines, was a member of the IFPMA Code Compliance Network (CCN), and also represented Japan to join the Expert Working Group to establish the APEC Mexico City Principles.

Dr. Jessica Santos is the Global Compliance Director in Kantar Health, the largest research company focused on the life sciences industry. Jessica is primarily responsible for providing oversight and support across the 40+ Kantar Health global offices in the area of regulation, interaction with clients, suppliers and others within Kantar Health, Kantar and WPP. Jessica is responsible for activities with regard to compliance laws/regulations, industry guidelines, and pharamcovigilance.

Jessica is a frequent speaker in major conferences. She has a PhD and a member of UK Ethics, EphMRA, BHBIA, PMRG and ISPOR ethic committee.

Andrew has over 5 years of professional experience working in Legal and Compliance. Andrew completed his studies at the University of Technology, Sydney earning a Bachelor of Law & Medical Science.

After graduating, Andrew took up a Compliance role at Novartis Pharmaceuticals Australia and New Zealand for 3 years before accepting a role at Sanofi ANZ in 2014 as the Country Compliance Officer. Andrew is responsible for managing the overall Compliance program including implementing effective SOPs and policies, conducting internal testing/monitoring and providing strategic compliance advice to the business units.

In 2015, Andrew received his Healthcare Compliance Certification from INSEAD, one of the top business schools in Europe. Andrew highly enjoys working on Compliance projects and finds it extremely rewarding partnering with the business units.

Cristopher Landrito is the Area Compliance Officer of Takeda Pharmaceuticals in Asia Pacific, based in Singapore. He is a qualified lawyer from the Philippines with experience in litigation, banking, tax, and in government regulatory matters, in addition to ethics and compliance. He has worked in various capacities in the banking, pharmaceutical and chemicals industries, as well as in the legislature. Before assuming his current role, Cris was the Regional Compliance Officer of the Merck KGaA Group in Asia Pacific, and, previously, its Legal Counsel for its ethical pharma division in Southeast Asia.

Masood Ahmed is the Vice President and Regional Compliance Officer, Asia & JPAC of Sanofi Group.

Masood started his career as finance professional with Beecham. He had held positions of CFO in Upjohn, Pharmacia, GSK & vice President Operations Pfizer before embarking on his role as Regional Compliance Officer with Schering-Plough.

Masood had significantly contributed in several merger and integration activities of giant pharmaceutical organizations which provided him unique opportunities of managing people, strategies and processes integration and shaping the corporate culture.

Masood has been intimately involved in the evolution of Pharmaceuticals industry's compliance environment in challenging markets in Asia.

Michael K. Loucks, a nationally recognized health care fraud prosecutor, joined the firm as a litigation partner in the Boston office in July 2010. With 25 years in public service, Mr. Loucks most recently was Acting U.S. Attorney and First Assistant U.S. Attorney for the District of Massachusetts, where he led major criminal and civil investigations, as well as many of the most high-profile health care fraud prosecutions of the past two decades.

Before serving as Acting U.S. Attorney, Mr. Loucks had a long history in the Massachusetts U.S. Attorney's Office. He was First Assistant U.S. Attorney (2005-2009); White Collar Crime Section Chief (2005); Health Care Fraud Unit Chief (1997-2004); and Health Care Fraud Coordinator (1992-2004).

Mr. Loucks speaks frequently at seminars and symposia on prosecutions, corporate compliance and litigation-related issues associated with the health care, pharmaceutical and medical devices sectors. He also writes extensively on these topics and is the co-author of Prosecuting and Defending Health Care Cases, the leading treatise in the area.

In 2011, Mr. Loucks received the Burton Award for Legal Achievement, which recognizes excellence in legal scholarship. He was selected in the Boston Business Journal's inaugural "Who's Who in Legal Services" (March 11, 2011).

Chi is a Forensic Technology Partner with EY's Fraud Investigation & Dispute Services practice in Shanghai. Chi has more than 14 years of experience in financial and enterprise data analytics and has worked in the United States, Australia and Greater China. He has extensive experience utilizing analytical software packages to join disparate data sets into a single repository, performing various analyses upon them, and identifying trends, patterns and outliers to detect fraud. Chi has led the design of a number of complex analytical engines leveraging predictive analysis, statistical modeling, data visualization, and text mining to help clients build continuous monitoring systems to identify fraudulent or high risk transactions timely and efficiently. He is also experienced in providing clients leading forensic data analytics solutions, including AML analytics, anti-bribery and anti-corruption analytics, Fraud Triangle analytics, third-party due diligence, business intelligence, text mining, and statistical anomaly detection. Chi has a Bachelor's Degree in Information Science from Peking University and a Master's Degree in Computer Science from Suffolk University. He is a Certified Fraud Examiner (CFE) and a Certified Information Systems Auditor (CISA).

Eugene Chen is a partner based in Hogan Lovells' Shanghai office, and is one of the few US-trained and experienced litigators located full-time in China to advise clients regarding advantages and liabilities of international dispute resolution. His practice focuses on cross-border disputes and investigations in the United States, China, and elsewhere in Asia.

Eugene began his career as a food and drug regulatory lawyer in Washington, DC, and has extensive litigation, compliance, and regulatory experience with the life sciences industry. For the past eight years, he has assisted clients with anti-corruption investigations and policy development in China, as well as enforcement actions by Chinese and U.S. authorities.

Seck Yee Chung leads the Firm's M&A, IT/C and Pharmaceutical &Healthcare practices in Vietnam. He is highly regarded in his field -- Chambers Global, Chambers Asia, and Asia Pacific Legal 500.

Mr. Seck has dealt with a wide range of investment projects and major M&A deals, and advised and assisted on corporate, commercial and regulatory compliance matters. This includes foreign direct investment, market access and licensing, private and public M&A, securities transfer and disclosures, competition and anti-corruption compliance, commercial promotions and marketing, data use and privacy, over a diverse range of industries, from consumer products, pharmaceuticals, medical devices, clinical trials, cosmetics, and food & beverage, to manufacturing, property, IT services, and aviation.

Laurent Clerc is regulatory affairs expert at BMI SYSTEM. He holds a Master of Health Law, a Master of Quality Assurance and an executive MBA. Co-founder of BMI SYSTEM, he has a professional background of more than 18 years serving the pharmaceutical industry and hospitals within consulting firms specialised in regulatory affairs.

Mohit is an Executive Director in Risk Consulting and leads the Life Sciences & Health Care industry in Southeast Asia. With 20 years of experience in Consulting and Life Sciences industries, he possesses in-depth expertise in enabling business growth strategies, transformations in Sales & Marketing, Finance and IT functions. He has extensive experience in delivering shared services, digital, enterprise applications and outsourcing initiatives.

Divina Ilas-Panganiban is a partner in Quisumbing Torres' Intellectual Property and Information Technology & Communications practice group. Her practice focuses on the protection of intellectual property rights, licensing and IP commercialization transactions, including franchising arrangements; regulatory and compliance matters, and IP litigation cases. She currently serves as a member of the Board of Directors of the Philippine Chapter of Licensing Executives Society International and is an accredited arbitrator of the Philippine Intellectual Property Office and the Philippine Dispute Resolution Center. Ms. Panganiban often serves as resource speaker in local and international seminars on IP and IT laws, including data privacy protection and social media.

Most recently, ten years in global Life Sciences Compliance and Governance supporting International markets - areas of focus include US Foreign Corrupt Practices Act, UK Bribery Act, Codes of Business Conduct, due diligence reviews, and supporting investigations and corrective actions.

Maria Eugenia (Maru) Quindimil is Senior Director APAC at GEC Risk Advisory LLC, the global governance, risk, integrity, reputation and crisis advisory firm (www.GECRisk.com) serving executives, boards, investors and advisors in diverse sectors, growth stages and industries, primarily in the Americas, Europe and Africa. Client assignments range from strategic to tactical, including enterprise and specific risk assessments, crisis planning, integrity program development, codes of conduct, and customized education from the boardroom to the shop floor.

Ms. Quindimil, the former Executive Director, Regional Compliance Officer, Asia for Merck Sharp & Dohme, Asia Ltd., led regional Compliance groups, comprising 26 professional staff in 20 Asia Pacific countries (10,000 employees) for 8 years. She successfully implemented the Foreign Corrupt Practices Acts (FCPA) in the region, the first Merck region to significantly reduce corrupt practice risk; used Six Sigma methodologies to simplify processes and develop an innovative scorecard and electronic platform to review compliance programs at the country level and ensure follow up monitoring; and improved key risk areas, including 90% reduction in samples management cases the first year. She co-created Asia Pacific Escalation, Investigation, Remediation and Recognition guidelines that were adopted by Merck globally. During the last two years, she created a strong process to handle Third Parties contracted in different capacities enhancing their compliance programs and governance processes.

In 2015 she was internationally recognized by the World Women Congress Leadership organization for her outstanding contributions in the region with the "Women Leadership Achievement Award." This award is given to outstanding women professionals who have demonstrated vision, flair, acumen and management skills in an organization making changes and achieving results sponsored by World Federation of Marketing professionals, Stars of the Industry Group, Asia Confederation of Business and World CSR Day.

Throughout a career that has spanned 25 years, Maru has applied her background in pharmaceutical and pharmacological research into the commercial pharmaceutical sector where she led the development, launch and market growth of several new products across a diverse range of geographic sectors. She has received several awards and recognition for achieving targets and significantly exceeding sales budgets. Her commercial background provides a broader strategic view of the role of compliance in operations, and has influenced management, regional leadership and boards of directors through innovative systems and processes. Her focus is to bring behavioral changes among leaders as well as rank-and-file.

Known for a flexible and situational leadership style, she is committed to enabling and optimizing the performance of teams from diverse backgrounds and across different work environments.

Maru has led APEC Pharmaceutical sector meetings for the implementation of Pharmaceutical codes of conduct, is a current Board member of Asia Pacific Compliance Group, and has been Chair and Speaker at Asia Pacific Pharmaceutical Compliance Congress for the last 4 years as well as a frequent speaker for IFPMA. A native Argentinian, Maru has lived and worked in Latin America, Europe, the USA and Asia Pacific region, and is fluent in English, Spanish and Portugese.

Maru has degrees in Biochemistry and Pharmacy from Universidad de Buenos Aires, Argentina; MBA from Instituto de Altos Estudios Empresariales from Universidad Austral, Argentina, Human Resources Master degree from Centro Estudios Financieros, Spain and graduated from Strategic Leadership Program from Institute of Leadership, Otago University, New Zealand.

Froilan Agatep is currently the sub-regional compliance officer, SEA of Merck. He is responsible for leading the corporate compliance program for all Merck entities in the Philippines, Malaysia, Indonesia, Thailand and Vietnam. He is a member of the compliance and governance committee of the Pharmaceutical Healthcare Association of the Philippines (PHAP). He finished his Bachelor of Arts (Major in Philosophy) and Bachelor of Laws degrees from the University of the Philippines and was admitted to the Philippine Bar in 2003.

Katsumi KOJIMA is a Corporate officer, Country Compliance officer Japan of Sanofi Group, based in Tokyo, Japan. He is a member of the Code Compliance Committee, the Japanese Pharmaceutical Manufacturers Association (JPMA) and a member of the International Federation of Pharmaceutical Manufacturers and associations (IFPMA) Code Compliance Network.

He has been working for compliance field in the pharmaceutical and medical device industries over ten (10) years. He engaged in a speaker and a panellist on compliance topics in various conferences, such as "How Do I Know It's Working? Key Performance Indicators, Metrics and More" at Asia-Pacific Economic Cooperation (Nanjing, China) in 2014, "Venues & Locations of Third Party Conferences: What is Appropriate" at Advanced Medical Technology Association and Medical Technology Association of Australia Compliance Conference (Singapore) in 2014 and "Australia and Japan transparency updates" at the Global MedTech Compliance Conference (Barcelona, Spain) in 2014.

He earned LLB from Waseda University (Tokyo, Japan) and LLM from Hitotsubashi University (Tokyo, Japan). In addition, he received certification from INSEAD Compliance Implementation Leadership 1 (Fontainebleau, France) and Seton Hall Law School Aisa-Pacific Healthcare Compliance (Singapore). Since 2010, he has served as a Visiting Lecturer at Kyoto Prefectural University of Medicine (Kyoto, Japan).

Cristopher Landrito is the Area Compliance Officer of Takeda Pharmaceuticals in Asia Pacific, based in Singapore. He is a qualified lawyer from the Philippines with experience in litigation, banking, tax, and in government regulatory matters, in addition to ethics and compliance. He has worked in various capacities in the banking, pharmaceutical and chemicals industries, as well as in the legislature. Before assuming his current role, Cris was the Regional Compliance Officer of the Merck KGaA Group in Asia Pacific, and, previously, its Legal Counsel for its ethical pharma division in Southeast Asia.

Masood Ahmed is the Vice President and Regional Compliance Officer, Asia & JPAC of Sanofi Group.

Masood started his career as finance professional with Beecham. He had held positions of CFO in Upjohn, Pharmacia, GSK & vice President Operations Pfizer before embarking on his role as Regional Compliance Officer with Schering-Plough.

Masood had significantly contributed in several merger and integration activities of giant pharmaceutical organizations which provided him unique opportunities of managing people, strategies and processes integration and shaping the corporate culture.

Masood has been intimately involved in the evolution of Pharmaceuticals industry's compliance environment in challenging markets in Asia.

Andy Bender is Polaris' founder. As a hands-on executive, Andy has been involved in a wide variety of compliance-related engagements for pharmaceutical and device manufacturers, ranging from policy development and process automation to organizational change. His expertise ranges from the sales and marketing to medical and clinical departments of the client organization. Andy is still involved in many of Polaris' client assignments, and has personally led many FMV, auditing and monitoring projects, as well as numerous international transparency reporting and HCP/O implementations.

Polaris has over 110 pharmaceutical and med device clients and employs a staff of more than 250, including five healthcare law attorneys. Polaris has offices in New York, Amsterdam, San Francisco, Paris and Boston.

Maija is an Australian qualified lawyer, having a combined LLB/BSC and LLM. Her focus has been on the Life Sciences industry, in which she has held various regional and international roles with both Pfizer and Novartis in Asia Pacific.

In her current role, Maija supports Russia and Asia Pacific for the Alcon Division within the Novartis Group as Associate General Counsel and Country Compliance Officer (for Singapore).

A large part of her work involves providing legal advice and assistance on complex corporate, commercial, BD&L, labour law and compliance matters.

Mohit is an Executive Director in Risk Consulting and leads the Life Sciences & Health Care industry in Southeast Asia. With 20 years of experience in Consulting and Life Sciences industries, he possesses in-depth expertise in enabling business growth strategies, transformations in Sales & Marketing, Finance and IT functions. He has extensive experience in delivering shared services, digital, enterprise applications and outsourcing initiatives.

Accountable for driving Abbott's Regional Ethics and Compliance Program in Asia region across its hugely diversified businesses i.e. Nutritional Products, Diabetes Care, Medical Optics, Vascular, Diagnostics, Pharmaceuticals and Molecular. One goal in mind: Nurture a robust organisation wide mindset of Triple Lenses of Responsibilities Framework -- Ethics, Economics/Finance and the Law.

An accomplished International Ethics & Compliance professional with combined 18 years of proven track record from scaling up to sustaining the Compliance Program together with Global and Regional key stakeholders. Experienced leading complex Audits and Investigations that resulted in a more robust internal controls structure and FCPA/ Anti-Bribery Anti-Corruption detective and preventive measures being put in place.

An outstanding people manager whose leadership philosophy is having a clear vision, empowering, coaching and the right intervention.

A Harvard Business School trained and well regarded industry thought leader. Rhys is currently the co-chairperson for Asia Pharmaceutical Compliance Congress, faculty member of Seton Hall University's Asia-Pacific Healthcare Compliance Program, founding member of the Asia-Pacific Healthcare Compliance Industry Group and member of the Harvard Business School Healthcare Alumni Association.

Dimas Adityo is an experienced compliance executive in Indonesia who has the hands-on experience on the pharmaceutical, healthcare and manufacturing businesses. Besides compliance, Dimas has also many experiences in internal control, internal audit and legal, and has been involved in many international assignments and reached many achievements on those areas of expertise. With this unique experiences in compliance, legal and audit, Dimas helped his organisations on the setting up of the compliance program from planning, execution until auditing/monitoring. Dimas is also an active member of a sub-committee in the International Pharmaceutical Manufacturers Group (IPMG) in Indonesia and has been actively setting up a Code for its IPMG members. Prior joining Sanofi Group Indonesia, Dimas has worked with Aventis, Deloitte and Citibank.

Cahyani Endahayu is an Associate Partner in the Corporate/Tax practice group. Her work includes handling the corporate/licensing and day-to-day work of several of the Firm's major clients and providing corporate and advisory support services to other clients in relation to corporate/commercial issues. Her specific interests and areas of law are pharmaceutical, retail/trading and foreign direct investment sectors.

Pofessional affiliations
- Member of the Indonesian Advocates Association (PERADI).

Education
- University of Gadjah Mada B.A. Law (1999)

Admission
- Cahyani obtained her Litigation Practice License and Advocate's Code of Ethics License in 2002.

Seck Yee Chung leads the Firm's M&A, IT/C and Pharmaceutical &Healthcare practices in Vietnam. He is highly regarded in his field -- Chambers Global, Chambers Asia, and Asia Pacific Legal 500.

Mr. Seck has dealt with a wide range of investment projects and major M&A deals, and advised and assisted on corporate, commercial and regulatory compliance matters. This includes foreign direct investment, market access and licensing, private and public M&A, securities transfer and disclosures, competition and anti-corruption compliance, commercial promotions and marketing, data use and privacy, over a diverse range of industries, from consumer products, pharmaceuticals, medical devices, clinical trials, cosmetics, and food & beverage, to manufacturing, property, IT services, and aviation.

Yuthana Sivaraks is currently a partner of Baker & McKenzie's Bangkok. He is primarily active in the Pharmaceuticals & Healthcare, Corporate and Commercial, IT/Communications and Intellectual Property Practice Groups. His responsibilities also extend to litigation in the Courts of Justice and Administrative Court, and regulations pertaining to government and administrative contracts. Prior to joining Baker & McKenzie he had been a judge advocate, serving in the Royal Thai Navy.

Yuthana earned his Bachelor of Law degree from Thammasat University, Thailand, and two masters degrees in law from Tulane University and Pennsylvania State University, both in the USA.

Juliet Lui is the Director of Advisory APAC of The Red Flag Group. Juliet is an experienced Australian lawyer who looks after the firm's Advisory Practice and client engagement across the Asia Pacific region.

Juliet has assessed, designed, implemented and managed compliance programmes for global multinational corporations across a wide range of industries. Juliet has in-depth experience and knowledge across extractives, logistics, medical technology and IT industries. She has led challenging onsite compliance assessments and investigations onsite in emerging markets including the UAE, Mongolia, Indonesia and China.

Juliet is an experienced and well-liked facilitator who has led ethics and leadership training to both compliance professionals and high-level management of large companies. She has facilitated such training in both English and Cantonese onsite at local client offices.